Bet1L Activators
Bet1L activators encompass a variety of compounds that indirectly enhance the functional activity of Bet1L by influencing the cellular processes and pathways in which it is directly involved. Bet1L plays a critical role in vesicle trafficking between the endoplasmic reticulum (ER) and the Golgi apparatus, a process that is essential for maintaining protein transport and cellular homeostasis. Compounds that disrupt the normal function of the ER-Golgi transport machinery or induce ER stress can indirectly upregulate the functional demand for Bet1L. For example, drugs like Brefeldin A and Golgicide A impair the general transport mechanisms between the ER and Golgi, thereby necessitating enhanced activity of Bet1L to compensate for these disruptions and maintain vesicular transport processes. Similarly, chemicals like Monensin and Nocodazole, by altering ion gradients and disrupting microtubules respectively, create a cellular environment that requires more robust Bet1L-mediated transport to ensure cellular function.
Moreover, compounds that induce ER stress, such as Tunicamycin, Thapsigargin, Withaferin A, andMG132, result in an increased demand for the ER-to-Golgi transport pathways to manage the accumulation of misfolded proteins and restore homeostasis. These stressors can indirectly enhance Bet1L activity by increasing the functional demand for its role in the secretory pathway. Additionally, inhibitors of post-translational modifications or signaling pathways, such as MLN4924 and H89, disrupt processes that are compensated by the vesicular transport system involving Bet1L. The activation of AMPK by AICAR also has implications for the upregulation of energy-dependent vesicular transport systems, potentially enhancing the role of Bet1L.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin is a carboxylic ionophore that disrupts Golgi function by altering ion gradients. Bet1L is involved in vesicular transport between the ER and Golgi, so the disruption of Golgi function by Monensin enhances the need for Bet1L's role in transport to maintain cellular homeostasis. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A is an inhibitor of vesicle trafficking that blocks protein transport from the ER to the Golgi apparatus. This blockade increases the demand for Bet1L's function in vesicular transport processes to bypass the inhibited pathways. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubules, which are necessary for vesicle transport, a process that Bet1L is involved in. The disruption caused by Nocodazole may enhance the functional activity of Bet1L to compensate for impaired transport mechanisms. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1 (GBF1), which is involved in ARF-dependent Golgi transport. Inhibition by Golgicide A enhances the reliance on Bet1L-mediated transport pathways as alternative routes. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
H89 is a protein kinase A inhibitor that can affect various signaling pathways, including those related to vesicle trafficking. Inhibiting PKA can enhance Bet1L's role in trafficking by upregulating compensatory pathways that Bet1L is part of. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $286.00 | 1 | |
MLN4924 is a NEDD8-activating enzyme inhibitor that disrupts neddylation, a post-translational modification important for vesicle trafficking. By inhibiting this modification, MLN4924 indirectly enhances Bet1L's function in essential vesicular transport. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which can cause ER stress and subsequently increase vesicular transport demands, indirectly enhancing Bet1L's functional activity in response to stress. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor leading to ER stress and increased calcium levels, which can enhance the vesicle formation and trafficking pathways Bet1L is involved in, as a cellular response to maintain calcium homeostasis. | ||||||
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal is an inhibitor of phosphatases that dephosphorylate eIF2α, leading to attenuated global protein synthesis and heightened ER stress. This stress potentially enhances the need for Bet1L's function in trafficking to alleviate the stress response. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR is an AMPK activator that can enhance cellular energy homeostasis mechanisms, indirectly upregulating vesicular transport processes where Bet1L is a key component, to meet the increased energy demands. | ||||||